DOD Awards $12.67 Million Contract Action to InBios International, Inc. to Increase Domestic Production Capacity of Rapid Point of Care COVID-19 Infection and Serological Response Tests

 Oct. 30, 2020

---

On October 30, 2020, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), awarded a contract action with a not-to-exceed value of $12.67 million to InBios International, Inc.  This effort will expand US based industrial production capacity of two point of care, rapid COVID-19 tests: SCoV-2 Ag Detect™ Kit, an antigen COVID-19 test, and SCoV-2 Detect™ IgM/IgG Kit, a serological COVID-19 response test.

This industrial base expansion effort will allow InBios International, Inc.  to increase their production capacity to 400,000 units per week by May 2021, a capacity increase of 20 times their current output.

The DOD’s Defense Assisted Acquisition (DA2) Cell led this effort in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT).  The Biomedical Advanced Research and Developmental Authority (BARDA) within the HHS funded this award through the Health Care Enactment Act (HCEA) in support of domestic industrial base expansion for critical medical resources.